Cancer Institute Director. Head & Neck Surgeon. Clinical Researcher focused on #immunotherapy. Relentlessly working to #FinishCancer @Providence Tweets my own
I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. @ChilesResearch
Providence is excited to announce Bryan Bell, M.D., as executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute @ChilesResearch. Walter Urba, M.D., Ph.D., wll retire at the end of the year. https://t.co/VNGawzp4uX
Thanks to Dr. Vinay Jain & @DAVAOnc for an outstanding inaugural peer forum at The Broadmoor!
After decades of negative trials, KEYNOTE-689 has transformed care, while 3 promising EGFR-targeting bispecifics are reshaping the R/M landscape.
Honored to shared our work @providence
Dr. @rbryanbell (Providence Cancer Institute) on neoadjuvant SBRT + anti-PD-1: in NIRT-2, pCR was 32%, mPR 72%, adjuvant RT was omitted in 76%, surgery was deescalated (no trach, no flap) in 48%, with 2-yr OS 90% and DFS 84%. #DAVAHeadAndNeck
Targeting cancer's 'dark matter’; Phase Ib (NCT04470024) was presented by Dr. R. Bryan Bell @rbryanbell@ProvHealth : off-the-shelf autophagosome vaccine DPV-001 + sequenced anti-PD-1 ± GITR agonist in R/M #HNSCC, any CPS, 1L–3L (n=18): ORR 44% (3 CR, 5 PR), median PFS 8.9+ mo, median OS 22.3+ mo. #DAVAHeadAndNeck
Enhancing TIL therapy in head and neck cancer: @rbryanbell@ProvHealth reviews tumor-reactive cell selection, IL-2 support and early AGX-148 clinical findings, alongside strategies to overcome the suppressive tumor microenvironment. #DAVAHeadAndNeck
For patients with resectable locally advanced #HeadAndNeckSquamousCellCarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. https://t.co/CFfn5W1NJh
My grandfather (L photo: front, 3rd from left; R photo: front, 2nd from left) was just 19 when he joined the Marines in 1942. He survived the South Pacific and went on to serve in the Army through 1972. On Veterans Day, remembering him and all who bravely served their country. 🇺🇸
Setting an unattainable objective. I wish it would come true, but curing all these diseases in the next 10 years is impossible.
And I'm very optimistic about the impact of AI for improving health.
Honored to keynote #NextGenHNC at @VanderbiltU . Thank you @TopfHNS for the kind invitation and gracious hospitality. Spoke on preserving regional immunity via neoadjuvant lymphatic-sparing immunoradiation in head & neck cancer. Great meeting!
Great discussions at @BeckersHR’s Oncology Summit in Chicago on 3 critical issues shaping cancer care:
🔬 Precision oncology: Our GigaPath/GigaTIME AI research
🏥 Access = treat access failures as a reportable safety signal
🧬 Sustaining innovation: research as a service line
To celebrate the birthday of William Shakespeare, I’m sharing a few lines from my most favorite sonnet, Sonnet 116. I’ve converted a few of my friends to its cause, and I’m hoping you’re next. Cheers!
You can hear the entire collection in “Patrick Stewart Performs the Complete Sonnets of William Shakespeare” available now: https://t.co/q5wEcT7vj2
@SimonAudio
#NationalShakespeareDay
Thanks to Mike Meyer & team for an outstanding #CCX2026! Inspiring discussions with leaders @HutchPresident@CliffordHudis@KimrynRathmell & many others on AI, innovation & cancer outcomes. My takeaway: Measure what matters to patients and ensure access to breakthroughs for all.
A milestone for biomarker-driven neoadjuvant immunotherapy! FDA approval of dostarlimab in dMMR rectal cancer points toward the ultimate goal: response-adapted therapy that may spare patients from surgery, chemo or radiation. #FinishCancer@Providence. https://t.co/pl6DTfehuD
Delighted to welcome Prof. Andriy Morgun from @OregonState as our EACRI visiting professor to talk about his work on the microbiome and digital twins. Great talk and wonderful discussion. Looking forward to start of a productive collaboration to #FinishCancer@providence
Prognostic value of baseline modified barium swallow for perioperative dysphagia in oropharyngeal cancer: Secondary analysis of ECOG-ACRIN E3311
https://t.co/0s2XuTtcpQ
An incredible #EACMFS2026 meeting in Athens! Deeply grateful to Prof. Nicholas Kalavrezos @londonhead_neck for the honor of delivering the Presidential Lecture—and for his friendship & gracious hospitality. Inspired by colleagues from around the world advancing surgical care.